Biography
Dr. Huang founded Ascendia in 2012 after fifteen years of pharmaceutical R&D experience at Pfizer, Baxter, AstraZeneca, and Roche. He has led the formulation development efforts for the successful transition of several oral and parenteral dosage forms from discovery through formulation, manufacturing, technical transfer and ultimately commercialization. Dr. Huang holds a Ph.D. in Pharmaceutics from the University of the Sciences in Philadelphia (formerly Philadelphia College of Pharmacy and Sciences) where he worked with Joseph B. Schwartz.Full
Research Interest
Vladimir Torchilin
University Distinguished Professor
Northeastern University
USA
Biography
Vladimir Torchilin graduated from the Moscow University with MS in Chemistry, and also obtained there his Ph.D. (1971) and D.Sc. (1981) in Polymer Chemistry, Chemical Kinetics and Catalysis, and Chemistry of Physiologically Active Compounds. In years 1968-1973, Torchilin made his research at the Chemical Department of Moscow State University. In 1974-1990 he was with the Institute of Experimental Cardiology, Russian Cardiology Research Center, where he founded the Laboratory of Enzyme Engineering of which he was a Head in 1981-1990. In 1991 Torchilin joined Massachusetts General Hospital and Harvard Medical School as the Head of Chemistry Program, Center for Imaging and Pharmaceutical Research, and Associate Professor of Radiology. Since 1998 Dr. Torchilin is with Northeastern University. In 1998-2008 he served as a Distinguished Professor and Chairman of the Department of Pharmaceutical Sciences. Since 2005, he is also the Director of The Center for Pharmaceutical Biotechnology and Nanomedicine. He also wrote more than 150 reviews and book chapters, wrote and edited 12 books including "Immobilized Enzymes in Medicine", "Handbook of Targeted Delivery of Imaging Agents", “Liposomes: A Practical Approachâ€, “Biomedical Aspects of Drug Targetingâ€, “Delivery of Protein and Peptide Drugs in Cancerâ€, “Nanoparticulates as Drug Carriersâ€, “Multifunctional Pharmaceutical Nanocarriersâ€, and 4 volume set “Handbook of Nanobiomedical Researchâ€, made over 250 invited lectures and seminars and holds more than 40 patents. He is also a Co-Editor of a novel book series on Biomedical Nanotechnology with Pan Stanford Publishing (World Scientific). According to Google Scholar, his H-index is 97 with >47,000 citations. His commitment to the engineering of drug delivery and targeting systems is also reflected in the numerous grants and contracts awarded to him by the NIH and various industries. His total funding over the years exceeds $30 M.
Research Interest
Engineering of biomedical polymers and polymeric drugs, medicinal enzyme stabilization and immobilization, drug delivery and targeting, drug carriers including liposomes and micelles, long-circulating drug carriers, novel imaging agents, antibody modification, and, more recently, experimental cancer immunology.
Biography
Randall Bjork is a neurologist from North Dakota who has been in practice for over three decades, mostly in Colorado, emphasizing humane and ethical dementia care. Twenty years ago, he advocated economy-of-scale dementia care with the concept of Lotus Health, which he will present here at our Dubai conference. He was involved in dementia treatment research from the early days of Cognex. He has conducted research with Aricept treatment and MRS evaluation in Down-Alzheimer patients. Dr. Bjork is co-author of a paper being presented here by his Swedish colleague, Dr. Lindau, from The University of Stockholm. He is now involved in a multi-center ketamine treatment protocol of treatment-resistant depression and post-traumatic stress disorder. He has lectured worldwide, contributed to the literature of cardiac arrest, stroke, myoclonus, Alzheimer disease, prionoses and has recently published a children's book, The ABCs of You, Volume I, available on Amazon. He has supervised mission medical work in Costa Rica and Nepal. He is an avid motorcyclist, restaurateur, cancer survivor and retired helicopter pilot.
Research Interest
Neurodegenerative diseases,Neuropharmacology
